Study of EBI-005 in Dry Eye Disease (DED)

Status unconfirmed · Phase 3 · Has a placebo group

Conditions studied: Dry Eye

In brief

This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye disease (DED). Approximately 188 subjects will be enrolled to either EBI-005 or vehicle at up to 15 centers in the United States (US) and Canada.

Key facts

Study ID

NCT02405039

Run by

Eleven Biotherapeutics

People needed

188

Starts

2015-04-01

Expected to finish

2016-07-01

Last updated by the study team

2015-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Newport Beach, California, United States
• Study site — Hamden, Connecticut, United States
• Study site — New Albany, Indiana, United States
• Study site — Louisville, Kentucky, United States
• Study site — Winchester, Massachusetts, United States
• Study site — St Louis, Missouri, United States
• Study site — Asheville, North Carolina, United States
• Study site — Mason, Ohio, United States
• Study site — Cranberry Township, Pennsylvania, United States
• Study site — Memphis, Tennessee, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.